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Abstract  
Background: Adults with bipolar disorder (BD) have higher rates of substance use disorders 
(SUDs) compared to the general population. SUD rates in young offspring/relatives of BD 
probands, as well as factors which drive those rates, are not as well-characterized.  
Methods: We aimed to examine SUD prevalence among adolescent/young adult offspring and 
relatives of probands with and without BD. Data were collected from five sites in the US and 
Australia during 2006-2011. Youth offspring/relatives (“Relatives of BD probands;” n=267; mean 
age = 16.8 years; ± 2.9 S.D.), identified through a proband family member with DSM-IV BD 
(Type I or II), were compared to offspring/relatives of control probands (“relatives of control 
probands;” n=149; mean age= 17.4 years; ± 2.9 S.D.). Logistic regression with generalized 
estimating equations was used to compare the groups across a range of substance use and 
SUD variables. Odds ratios were calculated for lifetime prevalence of substance outcomes.  
Results: Bivariate analyses showed DSM-IV SUDs were more prevalent among relatives of BD 
probands than among relatives of control probands (29% vs. 18%; p=0.01). Generalized 
estimating equation models showed BD mood and childhood-onset externalizing disorders in 
adolescent and young adult relatives to each significantly increase the odds (OR=2.80-3.17; 
p<0.02) for the development of several substance variables among all relatives, whereas the 
risk of SUDs in relatives was not increased when the relatives had no mood or externalizing 
disorders themselves.  
Conclusion: Relatives of BD probands with lifetime mood and externalizing disorders report 
more substance use/SUDs than relatives of control probands. In contrast, SUD outcomes in 
relatives of BD probands without mood or externalizing disorders were no different from control 
relatives without psychopathology. Early recognition and treatment of psychiatric disorders may 
lead to less substance use in this highly vulnerable population.  
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1. Introduction 
 The association between substance use disorders (SUDs) and mood disorders, 
particularly bipolar disorder (BD), has been well documented [1-4]. Estimates of lifetime 
comorbidity of BD and SUDs range from 16-54% [5, 6], with a recent meta-analysis finding a 
mean prevalence of 33% for comorbid BD and SUDs [7]. This comorbidity is particularly 
important from a prognostic standpoint, with multiple studies documenting significantly worse 
mental and physical health outcomes in individuals afflicted by both SUDs and BD [8, 9]. SUDs 
complicate treatment and course of BD, and vice versa. Co-occurring SUDs have been shown 
to be particularly associated with increased frequency and duration of mood episodes, 
increased preoccupation with suicide, decreased treatment compliance and more severe 
cognitive impairment in individuals with BD [3, 10]. Tobacco is the most commonly used drug of 
abuse among individuals with BD and is used 1.5-3 times more often than in the general 
population [11-14]. Tobacco use is of particular interest given recent evidence of earlier death 
rates in both men and women with BD, driven partly by tobacco-related illnesses [15]. Alcohol, 
cannabis, and cocaine are the next most commonly misused substances among individuals with 
BD [3]. Explanatory models postulate that substance use is elevated among individuals with BD, 
compared to the general population, because of common risk factors. These common risk 
factors may increase expression of a range of self-regulatory deficits which may manifest in 
symptoms of mood disorders or SUDs [16]. 
Prominent models of addiction liability have largely focused on trajectories toward SUDs 
from childhood externalizing disorders [17-20]. Pathways toward SUDs among youth with BD 
diagnoses are also becoming increasingly well characterized [21-24]. In youth, the combination 
of conduct disorder and BD has been associated with especially high rates of SUDs in relatives 
[21], indicating an overlap between the risk factors for BD and SUDs. Genome-wide association 
analysis has provided evidence of a significant genetic overlap in the risk factors of BD and 
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SUDs [25]. However, the relative influence of a family history of BD and other risk factors (e.g., 
adolescent psychopathology, parental SUDs, etc.) on SUD development in BD remain unclear, 
as does information pertaining to relative age of onset of each disorder category.  
Understanding mechanisms leading to an underlying SUD in BD are essential to the 
development of appropriate preventive and treatment interventions.  For example, if parenting 
practices associated with having BD are driving the effect, modifying parental behavior should 
become the focus of intervention development.  If adolescent psychopathology is driving the 
effect, preventing or treating youth disorders should become the focus of study. 
Examination of adolescent/young adult relatives of BD probands provides an opportunity 
to study SUD/substance use and psychiatric disorders as they develop. Increased risk for SUDs 
in relatives of individuals with BD are hypothetically attributed to several factors. First, the 
occurrence of high rates of psychopathology in offspring of BD probands [26] may increase risk, 
as higher rates of SUDs have been associated with a range of mental disorders. Second, 
shared genetic loading for BD as well as SUDs is higher in relatives of BD probands. Identified 
genes likely influence affective and reward brain circuitry abnormalities linked with both SUD 
and BD [27]. Third, stressors associated with having relatives with BD may also increase risk for 
SUDs [28].  
Several recent studies have reported on rates of SUDs in offspring of BD probands. In a 
Canadian sample, 24% of prospectively followed adolescent and young adult offspring of BD 
probands (aged 12-25) were found to have lifetime SUD, with cannabis being the most common 
substance abused [29]. Being male and having a prior mood disorder were risk factors for 
offspring developing a SUD [29]. Similarly, in the Dutch Bipolar Offspring Study, lifetime 
prevalence of a SUD was 28% in offspring of BD probands, when assessed at follow up during 
young adulthood [30]. BD in parental probands has also been shown to predict offspring SUD, 
while MDD in parental probands in the same sample did not [31]. SUDs and substance use are 
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relatively common in the general adolescent population [32]; thus, comparisons with relatives of 
control proband parents are warranted in order to determine if their SUD rates differ from 
relatives of control probands whose families do not have identified BD. The Pittsburg Bipolar 
Offspring Study (BIOS) reported that 20% of relatives of BD probands had SUDs at follow up at 
mean age of 18.1 years, compared to only 10% of community control relatives of control 
probands [33]. In sum, SUD rates in young adult relatives of BD probands range from 20-28% 
and appear to be greater than those in relatives of control probands. However, while high rates 
of comorbid psychiatric and SUDs have been established, the relative influence of proband 
SUDs/psychopathology and relatives own psychopathology on SUD outcomes in relatives of 
probands with BD has not been well characterized in prior studies. 
The relationship between parental/relative BD and SUDs and adolescent 
psychopathology and SUDs remains poorly defined. We hypothesize, for our primary research 
question, that offspring/relatives of probands with BD (“relatives of BD probands”) will be more 
likely to manifest SUDs, compared to youth offspring/relatives of control probands (“relatives of 
control probands ”), even after adjusting for relative mental health diagnoses. We also report 
three exploratory analyses, hypothesizing that: (1) Parental SUDs, Parental BD and relative 
psychopathology will all be associated with increased odds for adolescent substance outcomes 
(2) Given the controversy surrounding the ages of onset of SUDs vs BD (e.g., some studies 
suggested that SUDs predict mood disorders [34-36] and others the reverse relationship [37-
39], with most conceding that a bidirectional relationship is also likely), we plan to study the 
relative age of onset of each type of disorder and predict the onset of mood disorders will occur 
prior to the onset of SUDs in both groups, given the relatively earlier emergence of these 
disorders, in general.  (3) Finally, we are unaware of any studies examining the relative age of 
onset of SUDs in BD relatives vs. control relatives.  We predict that relatives of BD probands will 
have earlier onset of SUDs than relatives of control probands, given greater rates of child and 
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adolescent onset psychopathology in BD relatives. To address these four topics, we examined 
the lifetime prevalence and age of onset of SUD outcomes and their relationship to parental 
SUDs and BD and comorbid youth psychopathology (i.e., mood, anxiety and externalizing 
disorders) in adolescent and young adult offspring/relatives of probands with and without BD. 
Given the young age of our sample, we examine the spectrum from subthreshold SUD 
symptoms to SUDs. 
2. Material and Methods 
2.1 Subjects 
As detailed in prior publications [26, 40, 41], information on participants was ascertained 
through the research database of the Bipolar High Risk Study Group. Relatives of BD probands 
were 12-21 year old offspring (81%) or siblings (9%) of a proband with BD, the majority of whom 
had BD, type I (89%). A small number (10%) were 2nd degree relatives of a BD proband in a 
family with multiple cases of BD. Control participants (“relatives of control probands”) were 
identified through proband parents with no BD or other major mood disorder or psychosis (or 
psychiatric hospitalization) themselves or in their first-degree relatives; Relatives of control 
probands were ascertained through general medicine clinics, motor vehicle records and campus 
advertising. Relatives of control probands were excluded only for substantial cognitive 
impairment, but could have psychiatric diagnoses. Only data from baseline interviews are 
presented here. Procedures were approved by institutional review boards at the 5 collection 
sites. Informed consent was acquired after an explanation of the study with the participant and 
parent or guardian, if the participant was less than 18 years (<16 in Australia). Adolescents 
assented to participate in the study. Relatives of probands with and without BD were recruited 
between June 2006 and June 2011.  
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2.2 Diagnostic Procedures  
DSM-IV-TR psychiatric diagnoses and ages of onset, including SUD diagnoses, were 
generated per best-estimate procedures using a modified Kiddie Schedule for Affective 
Disorders with adolescent and parent report (K-SADS-BD; 
http://www.bipolargenes.org/hrdownloads.html), followed by consensus diagnosis [26]. 
Diagnoses and age at onset determinations were made on the basis of consensus between two 
clinicians, including information from direct interview, medical records, and parent interview. 
Clinicians were blind to the group status of the subject. Interrater reliability was established by 
distributing identical diagnostic packages to multiple diagnosticians at the four US sites and 
collating the results. Each site had between 2-5 assessors (most had 2).  Each US participant 
was assessed twice, while each Australian participant was assessed once. 
 
Kappa for interrater reliability for major affective disorder diagnosis was 0.82; kappa for 
other disorder categories ranged from 0.70 to 0.85. The best estimate process also included 
consensus ratings of lifetime symptom severity for three categories: mood, anxiety, and 
behavior, using a seven-point scale. Weighted kappa for ratings for mood symptoms was 0.77, 
for behavioral symptoms, 0.70 and for anxiety symptoms 0.67. Between site variability was 
addressed by holding joint training exercises for interviewers, regular conference calls for staff 
from all sites to standardize assessment methods and to exchange diagnostic packets for 
reliability.  Also, 4/5 sites recruited their own controls to reduce site variability in case-control 
comparisons.  
 
DSM-IV-TR diagnoses of substance abuse, dependence, and “not otherwise 
specified-related” (NOS) were obtained for alcohol, cannabis, stimulants, sedatives, cocaine, 
opiates, PCP, hallucinogens, and solvents. An NOS SUD diagnosis was made if a participant 
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did not meet the requisite 1 or greater DSM-IV-TR criteria but instead reported 1 or more 
subthreshold symptoms on the K-SADS assessment. The NOS category was included because, 
in another study with a different sample, up to 40% of participants with substance problems not 
meeting full DSM criteria for abuse or dependence have been reported to show problematic use 
at 3-year follow up [32]. To increase statistical power, in addition to traditionally defined DSM-IV-
TR SUDs variables, measures of substance abuse, dependence, nicotine use variables (see 
below) and NOS diagnoses were aggregated to create a “problematic substance use” (PSU) 
variable for all of the previously listed substances. Participants with nicotine use, any DSM-IV 
use disorder or NOS use disorder criteria were coded as having PSU, while participants with 
none of these were coded as not having PSU.  Separate variables, termed “problem use” were 
also calculated individually for each drug of abuse (e.g., problem cannabis use).. Problem use 
was coded for an individual, if any lifetime abuse, dependence or NOS diagnoses were present. 
Thus, with the exception of tobacco, we focus on use that was associated with reports of 
impairment (i.e., problem use linked to DSM-IV criteria for SUDs), rather than just cases where 
use alone was identified. The tobacco section of this version of the K-SADS was not designed 
to diagnose DSM-IV nicotine dependence; therefore, the participants were not assessed for 
nicotine dependence. However, “nicotine use” was defined here as “ever smoked” or “ever 
chewed” or “currently use.”  
DSM-IV-TR diagnoses for most non-substance psychiatric disorders (Supp. Table 1) 
were aggregated into 3 main categories: mood (major depression, bipolar disorders, dysthymia, 
mood disorder not otherwise specified, cyclothymia), anxiety (generalized anxiety disorder, 
post-traumatic stress disorder, separation anxiety, specific phobias and anxiety disorders, not 
otherwise specified) and externalizing disorders (attention-deficit/hyperactivity disorder, 
oppositional defiant disorder, conduct disorder). An individual was coded as belonging to any of 
these categories (e.g., mood) if they met lifetime criteria for any of the disorders listed (e.g. 
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major depression, bipolar disorders, dysthymia, mood disorder not otherwise specified, 
cyclothymia). As the number of relatives with BD I or II diagnoses was very low in this 
adolescent/young adult sample, all mood disorders were collapsed into the ‘mood disorder’ 
variable. An individual may have qualified for membership in one or more categories. Disorders 
that occurred in <3 participants in any category were not presented in tables. Disorders with <10 
participants in both groups were not analyzed individually, but were included in aggregated 
variable categories.  
2.3 Statistical Analyses 
Demographic and clinical characteristics in this cross-sectional analysis of an ongoing 
longitudinal study were compared between relatives of BD probands (n=267) and relatives of 
control probands (n=149) using an independent samples t-test for quantitative variables or a 
chi-square test for categorical variables. All analyses were completed using SPSS 21.0 (IBM). A 
Bonferroni corrected alpha of 0.01 was used for the primary analysis (correcting for 4 between 
group comparisons: SUDs, PSU, nicotine use, alcohol use disorders), while exploratory 
analyses utilized an uncorrected alpha of 0.05. Age, sex and ethnicity were covariates. 
Adjustment for the presence of non-substance psychiatric disorders was implemented, when 
specified.  
For our primary analysis, we were interested in differences in SUDs, sub-threshold 
disorders and nicotine use between relatives of probands with and without BD. Substance 
variables were compared across the two groups with binary logistic regression models. 
Generalized estimating equations (GEE) were used with the regression model to account for the 
correlation between siblings. All comparisons were adjusted for age, sex, and ethnicity. 
Subsequently, differences between relatives of probands with and without BD in prevalence of 
drug and alcohol use disorders, PSU and nicotine use were examined using logistic regression 
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with GEE while also controlling for comorbid psychopathology (i.e., mood, anxiety and 
externalizing disorders).  
The existing literature has not adequately addressed factors (i.e., parental mental health, 
adolescent mental health, parental SUD) that may explain increased SUDs in BD offspring and 
relatives.  While we are underpowered for a definitive analysis, logistic regression with GEE was 
used for an exploratory analysis to determine the relative contribution of each of the following 
independent variables to the odds of relative substance misuse/SUD vs. no substance 
misuse/SUD, across the entire sample: gender, ethnicity, parental BD diagnosis, parental SUD 
diagnosis, relative’s mood disorder, externalizing and/or anxiety disorder diagnoses (presented 
in Table 2). The substance-related outcomes were any lifetime DSM-IV SUD (excluding nicotine 
and NOS), PSU and nicotine use. We also report the goodness of fit of each model as 
independent variables were individually added, using the Corrected Quasi Likelihood under 
Independence Model Criterion (lower QICC implies better fit; Supp. Table 3).  In addition, we 
report a breakdown of the frequency of diagnosis with problematic substance use in relatives of 
probands with BD vs. relatives of control probands, with or without psychopathology (Supp. 
Table 2) and the proportions of participants with PSU and/or nicotine use, according to group 
and the presence of the various categories of comorbid psychopathology (Figure 1). 
 Finally, for another exploratory analysis, we used three different methods to examine 
differences in age of onset of SUDs between groups. First, using earliest age of onset of the 
disorders, Kaplan-Meier survival curves were calculated for PSU and nicotine use, and the log 
rank test P values were examined. Second, the age of onset of PSU, cannabis, alcohol and 
nicotine use were compared across groups using linear regression with GEE. Third, t tests 
compared age of onset of SUDs between groups in a subset of participants that included only 
the oldest sibling in each family (as t tests do not control for sibling relatedness). Finally, t tests 
comparing age of onset of mood/anxiety and SUDs in participants with both types of disorders 
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were compared within groups (relatives of probands with BD vs. without BD), but only in the 
subset of participants who were not related to each other (because of lack of control for sibling 
relatedness with t tests). We also compared the average ages of onset of BD vs PSU and, 
separately, age of onset of unipolar depression vs. PSU, across the entire sample.  We 
repeated that analysis for alcohol use disorders (AUDs). 
3. Results 
Relatives of BD probands (mean age = 16.8 years; ±2.9 S.D.) comprised 267 
adolescent/young adult participants. This sample included subjects from 183 families, 121 with 
a single offspring, 44 with 2 offspring, 13 with 3, 2 with 4, 1 with 5, and 1 with 6. Males 
comprised 49.4% of this sample. There were 149 relatives of control probands (mean age= 17.4 
years; ±2.9 S.D.) ascertained from 114 families, 87 with a single offspring, 21 with 2 offspring, 5 
with 3, and 1 with 5. Males made up 53% of this population. The two groups differed on ethnicity 
(rates of European ancestry in Relatives of BD probands =89.1%; relatives of control probands 
= 61.7%; 2=78.4; p=0.001), but not in age (t=-1.94; p=0.053), sex (2=0.491; p=0.484) or 
socioeconomic status (paternal years of education: Relatives of BD probands: mean = 15.8 
(S.D. =2.6); relatives of control probands: mean = 16.9 (S.D.=3.4); t=1.96; p=0.42). Body mass 
index (Relatives of BD probands: mean=24.5 (S.D. =5.7); relatives of control probands: mean 
=22.7 (S.D.=4.5); t=1.9, p=0.06) and ever repeating a year of schooling (Relatives of BD 
probands: 6.8% relatives of control probands:  10.9%;  2=1.41; p=0.24) also did not differ 
significantly between groups. 
3.1 SUD rates in relatives of BD probands vs. relatives of control probands  
Comparisons in rates of SUDs/substance use between relatives of probands with and 
without BD revealed that SUDs (non-nicotine; p=0.01), nicotine use (p=0.004) and PSU 
(p=0.01) were observed more often in relatives of probands with BD while controlling for 
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demographics and sibling relatedness (Bonferroni corrected alpha = 0.01; Table 1). For nicotine 
use, effects for ethnicity (highest use in multi-ethnic participants, lowest use in those of African 
descent; p=0.001) and age (older > younger; p=0.001) were found, but no effects of gender 
(Table 1). Of note, alcohol use disorders did not differ between groups. Significant effects of age 
(older > younger; p=0.001) but not ethnicity or gender were found for SU. There were no 
differences in rates of PSU (20.1% vs 16.9%; p=0.50) or substance abuse and dependence 
(9.0% vs. 5.9%; p=0.3) between the US and Australian sites. Rates of SUDs reported at each 
site are reported in Supplementary Table 4. 
When the effects of mood, anxiety and externalizing disorders were controlled for, the 
prevalence of SUDs, PSU, nicotine use and alcohol use disorders were no different in relatives 
of probands with and without BD (all p>0.05; findings not presented in a table). Thus, non-
psychiatrically ill relatives of probands with BD were no different than relatives of control 
probands in terms of SUDs/substance use. 
3.2 Non-substance psychopathology in relatives of probands with and without BD 
Relatives of probands with BD had higher rates of any BD disorder (p=0.030), social 
phobia (p=0.004), GAD (p=0.006) and enuresis (p=0.014), after accounting for demographics 
and sibling relatedness (Supp. eTable 1). Total mood (p=0.001) and total anxiety (p=0.001) 
disorder diagnoses were more prevalent in relatives of probands with BD, with a trend toward 
higher rates of externalizing disorders (p=0.053). Rates of mood, externalizing and anxiety 
disorders across the 5 recruitment sites are presented in Supplementary Table 4. 
3.3 Relationship of offspring psychopathology with BD and SUD family history  
Participants (%) with PSU and/or nicotine use, according to group and co-morbid mental 
health concerns, are displayed in Figure 1. Aggregated psychiatric diagnoses can be found in 
Supplemental Table 2.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 15 
The odds ratios for relative assignment to PSU, nicotine use, or SUD categories, after 
accounting for demographic factors, parental BD and SUD and offspring psychiatric disorders, 
are also presented in Table 2. Increased age significantly increased the odds of developing 
each substance variable, as would be expected (OR range: 1.48-1.5; p<0.0001). Ethnicity and 
gender did not impact the odds of diagnosis of any substance outcome, after accounting for all 
other variables in the model. Surprisingly, neither proband BD nor SUD increased the odds of 
relative drug use, after accounting for all other variables in the model (Table 2). Relative’s own 
psychopathology, however, did increase the odds of development of drug use, as follows: (1) 
PSU was 2.8 times more likely (p=0.003) in youth with externalizing disorders. For all models, 
only the addition of demographic factors and the presence of offspring psychiatric disorders 
improved model fit (Supplemental Table 3). (2) Nicotine use was 3.17 times more likely 
(p=0.017) in youth with mood disorders and (3) DSM-IV drug and alcohol use disorders (SUDs) 
were 3.00 times more likely (p=0.020) in youth with mood disorders. 
3.5 Age of onset for psychopathology and substance use 
Kaplan-Meier survival curves demonstrated no significant differences in age of onset or 
course of PSU or nicotine use between groups (p=0.562 and 0.221 respectively; Supp. Figures 
1 & 2). Similarly, neither whole sample regression findings (PSU: p=0.707, Cannabis: p=0.264, 
Alcohol: p=0.711, Nicotine: p=0.816), nor direct t-test comparisons of ages of onset of PSU 
(p=0.290) or nicotine use (p=0.447) differed between groups (Table 3). However, mood 
disorders occurred significantly earlier (p<0.007) in the BD relative (siblings removed; 13.1 
years) vs. control (15.6 years) sample. In this subset, on average, the first onset of mood 
disorders occurred significantly earlier than the earliest onset of any SUD for both groups (13.1 
years vs.15.3 years for the Relatives of BD probands , p<0.0001; 15.6 years vs. 16.1 years for 
relatives of control probands , p<0.0001; Figure 2).  The age of PSU onset occurred around the 
same time as the onset of BD (10.4 vs. 12.4 years; p=0.49; n=7) and unipolar depression (14.3 
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vs. 14.8 years; p=0.40; n=51), across the entire sample. When we examined the onset of AUDs 
compared to types of mood disorders, we found that BD (12.4 vs. 16.8 years; p=0.001, n=9) and 
unipolar depression (14.8 vs. 16.8 years, p=0.0001; n= 43) occurred significantly earlier than the 
onset of AUDs. 
4. Discussion 
This study compared SUD development in young adult and adolescent relatives of 
probands with and without BD. Our primary finding was that rates of SUDs and substance use, 
except alcohol, were higher in relatives of BD probands compared to relatives of control 
probands, with offspring psychopathology appearing to partly account for such group 
differences in SUDs. We also found similar rates of SUDs compared to other studies on the 
offspring of BD probands [29-31, 33], with a lifetime DSM-IV SUD rate of 28% in the relatives of 
BD probands.  In sum, this analysis suggests that the presence of parental BD is significantly 
associated with adolescent SUDs, as hypothesized, although this effect appears to be 
influenced by the presence of other psychiatric diagnoses. Youth psychopathology was the 
most important contributor to the studied substance outcomes in this high-risk adolescent 
sample. When non-substance psychopathology in offspring was accounted for, parental BD or 
SUD was no longer a significant contributor to risk for SUDs. This suggests that substance use 
outcomes among those with a family history of BD or SUD are influenced by the presence of 
psychiatric diagnoses. This finding is consistent with results from the National Comorbidity 
Survey Replication Adolescent Supplement (NCS-A) demonstrating that youth psychopathology 
is the most important predictor of SUD development, across the general population [42]. 
Previous research in adolescents has demonstrated that individuals with a family history of BD 
have more than three times the prevalence of mood disorders than those without such a family 
history [26]. Therefore, we speculate that youth psychopathology, related to the family history of 
BD, is likely the primary risk factor for the development of an SUD in our sample [26, 43]. We 
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fail to find independent effects of gender or ethnicity in our analyses, perhaps because 
offspring/relative psychopathology primarily accounted for demographic effects.  
Given that nicotine variables were included in the PSU variable and appeared to be 
contributing to the PSU findings, we examined these separately. Relatives of BD probands were 
more than twice as likely to have used nicotine than relatives of control probands. Nicotine 
users (who may have been using multiple other substances as well) accounted for the overall 
difference in prevalence of SUDs among relatives of BD probands. Heavier and earlier use of 
inhaled substances such as nicotine and cannabis may partly explain increased death and 
medical comorbidity rates [15] among individuals who may eventually develop BD or other 
major psychiatric disorders.  
For our first exploratory analysis, we found that nicotine use and SUDs were related only 
to youth mood disorders, but not externalizing or anxiety disorders, a surprising finding given 
prior links of SUDs to childhood externalizing disorders [44, 45]. However, this finding parallels 
our previous report showing that externalizing disorders (and anxiety disorders) among relatives 
of BD probands were primarily seen in subjects with mood disorders [26].  PSU, however, was 
associated with youth externalizing disorders, consistent with a large, existing literature relating 
these two clinical presentations [46, 47]. Future longitudinal work with larger samples is needed 
to substantiate the specific psychopathology/SUD relationships.  
We also examined the chronological order of psychiatric disorders in relation to SUDs, 
hypothesizing that youth who have already developed mood disorders will have developed 
these prior to substance misuse and SUDs. Notably, the retrospective report of the age of onset 
was earlier for mood disorders than PSU in both groups, but mood disorders occurred earlier in 
relatives of BD probands  vs. relatives of control probands . While the availability of substances 
is relevant here, these findings also speak to the link between mood disorders and SUDs across 
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development. As described earlier, some studies have suggested that SUDs predict mood 
disorders [34-36] and others the reverse relationship [37-39], with a bidirectional relationship 
also possible.  Preisig et al [48] distinguished unipolar from bipolar depression, finding that 
alcohol use disorders (AUDs) occurred after the onset of BD.  In contrast, unipolar depression 
tended to occur after the onset of AUD. Less is known of this relationship with regard to other 
drugs of abuse. Ours is the first study to directly examine the order of emergence of mood 
symptoms vs. substance use/SUDs in a sample at high risk for BD; and we found that mood 
disorders appeared first. When we examined ages of onset of BD and unipolar depression vs. 
PSU separately, we found that the average age of onset of PSU was approximately the same 
as the age of both forms of depression. However, we found both types of mood disorders to 
occur before the onset of AUDs, replicating Preisig’s findings in BD, but contradicting their 
findings in unipolar depression. We note our small sample size with available age of onset data, 
particularly in comparisons involving youth with BD. 
Our last exploratory hypothesis was that relatives of BD probands would have an earlier 
age of onset of SUDs than relatives of control probands; however, our survival analysis showed 
no group differences. It is possible that our analysis was underpowered, given the relatively 
small number of individuals who became problematic substance users by late adolescence. It is 
also worth noting that substance use in early adolescence is closely linked to the opportunities 
to use drugs of abuse [49].  
Several limitations are noted. First, substance diagnoses were assessed with both 
parent and youth self-reported data, but without biological drug screening. Second, the groups 
were not initially matched on ethnicity, however we adjusted for these differences in our 
analyses. Third, as the sample has not fully passed through the period of risk, additional SUDs 
would be expected to emerge over time. Fourth, given the exploratory nature of several of our 
research questions, we did not correct for multiple comparisons in those analyses. Fifth, we 
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acknowledge that the risk for SUDs conferred by non-offspring relatives (i.e., siblings, nieces) 
may differ from that conveyed by offspring and these findings may therefore differ from those of 
other samples comprised exclusively of offspring. Finally, we cannot exclude the possibility that 
factors other than those that were measured and reported (e.g., cognitive traits, peer group, 
stressful life events, severity of illness) may account for differences between the groups.  
5. Conclusions 
 In summary, SUDs, PSU, SUDs and nicotine use were more common in relatives of 
probands with BD, with these differences largely accounted for by co-existing mood or 
externalizing disorders. These findings suggest that prevention and treatment of psychiatric 
disorders in adolescents may modify the course or prevent the development of SUDs, 
particularly in youth with a family history of BD.  
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Figure 1. Problematic Substance Use Prevalence Percentage of individuals with problematic 
substance use (PSU; top) and nicotine use (bottom), divided relatives of bipolar disorder (BD) 
probands and relatives of control probands, according to categories of psychopathology: anxiety 
(n=108), mood (n=104), externalizing (n=83), none (n=279).  Error bars represent the standard 
error. 
Figure 2. Age of Onset Average age of onset of mood disorder vs. problematic substance use 
in relatives of bipolar disorder (BD) probands and relatives of control probands. *Difference at 
p<0.0001. 
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Table 1 Substance use outcomes in relatives of BD probands vs. relatives of control probands.  
Group differences were derived using GEE with logistic regression to address sibling relatedness, 
controlling for age, gender and ethnicity.  Primary substance-related variables are bolded. Percentages 
represent the subset of the relative of BD proband or relative of control proband sample that met criteria 
for each substance variable. Odds ratios represent the odds a relative of a BD proband is more likely to 
meet criteria for a given substance outcome than a relative of a control proband. *p value of less than or 
equal to 0.05.  BD=Bipolar Disorder 
 
Relatives 
of BD    
n= 267 
Relatives 
of Controls 
n= 149 
Odds 
Ratio 
[95%CI] P value 
Any substance use 
disorder, excluding 
nicotine                  
77 
28.8% 
27 
18.1% 
1.8  
[1.1-3.0] 0.011* 
Alcohol abuse or 
dependence                     
 20 
7.5% 
6 
4.0% 
1.0 
[0.7-6.0] 0.208 
Problematic substance 
use                    
88 
33.0% 
31 
20.8% 
 2.0 
[1.2-3.5] 0.01* 
Cannabis problems  
20 
7.5% 
6 
4.0% 
1.9 
[0.75-4.9] 0.184 
Stimulant problems 
6 
2.2% 
4 
2.7% - - 
Sedative problems    
3 
1.1% 
2 
1.3% - - 
Cocaine problems        
6 
2.2% 
2 
1.3% - - 
Opiate problems       
2 
0.7% 
1 
0.7% - - 
PCP problems            
1 
0.4% 
1 
0.7% - -  
Hallucinogen problems  
3 
1.1% 
1 
0.7% - - 
Solvent problems       
4 
1.5%
2 
1.3% - - 
Other drug problems  
5 
1.9% 
4 
2.7% - - 
Ever smoked tobacco  
63 
23.6% 
16 
10.7% 
2.6 
[1.4-4.6] 0.005* 
Ever chewed tobacco  
15 
5.6% 
1 
0.7% 
8.8 
[1.2-67.4] 0.014* 
Current tobacco use  
17 
6.4% 
2 
1.3% 
5.0 
[1.1-21.9] 0.026* 
Nicotine use 
63   
23.6% 
16        
10.7% 
2.6 
[1.4-4.6] 0.004* 
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Table 2.  Odds ratios of relatives of probands with and without BD for developing a lifetime diagnosis of 
problematic substance use, nicotine use or drug and alcohol use disorders (vs. reference category of no 
disorder).  Results from logistic regression with GEE, accounting for demographics, proband bipolar 
disorder or substance use disorder (SUD) and relative’s own psychiatric disorders. * p value of less than 
or equal to 0.05; Disorders included under mood disorders were:  Bipolar (BD) type I, BD type II, BD 
NOS, schizoaffective disorder-bipolar or depressed type, single episode unipolar depression, unipolar 
recurrent depression, adjustment disorder with depressed mood, depressive disorder NOS, mood 
disorder secondary to a medical condition, dysthymic disorder, and cyclothymic disorder. Anxiety 
disorders included: obsessive compulsive disorder (OCD), panic disorder with and without agoraphobia, 
social anxiety disorder, specific phobia, generalized anxiety disorder (GAD), separation anxiety disorder, 
acute stress disorder, adjustment disorder with anxious mood, and PTSD. Externalizing disorders were 
defined as conduct disorder, oppositional defiant disorder (ODD) and ADHD (all subtypes). 
Abbreviations: SUD=substance use disorder; OR=odds ratio; CI=confidence interval; BD=bipolar 
disorder 
 
 
Wald 
Chi-
square p-value OR [95% CI] 
Problematic Substance Use 
   Presence of Parental Bipolar Disorder 1.66 0.198 2.42 [0.6-9.3] 
Presence of Parental SUD  2.34 0.126 0.39 [0.1-1.3] 
Presence of Relative Mood Disorder 3.78 0.052 1.17 [1.0-3.2] 
Presence of Relative Externalizing Disorder 9.02 0.003* 2.80 [1.4-5.5] 
Presence of Relative Anxiety Disorder 1.31  0.13 3.27 [.8-2.6] 
Nicotine Use 
   Presence of Parental Bipolar Disorder 0.02 0.889 0.92 [0.3-3.1]  
Presence of Parental SUD  1.63 0.201 2.23 [0.7-7.7] 
Presence of Relative Mood Disorder 5.67 0.017* 3.17 [1.2-8.2] 
Presence of Relative Externalizing Disorder 0.54 0.538 1.43 [0.5-3.7] 
Presence of Relative Anxiety Disorder 0.01 0.922 0.95 [0.4-2.5] 
DSM-IV Drug and Alcohol Use  
Disorders (excluding nicotine) 
   Presence of Parental Bipolar 0.08 0.779 1.19 [0.4-3.9] 
Presence of Parental SUD  0.36 0.549 1.47 [0.4-5.1] 
Presence of Relative Mood Disorder 5.40 0.020* 3.00 [1.2-7.6] 
Presence of Relative Externalizing Disorder 0.38 0.537 1.35 [0.5-3.5] 
Presence of Relative Anxiety Disorder 0.46 0.489 1.40 [0.5-3.7] 
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Table 3.  Independent samples t-test comparison of the average age of onset (AAO) of first lifetime 
substance use disorder (SUD) diagnosis or nicotine use (NU) between relatives of BD probands and 
relatives of control probands, in the sample excluding siblings. (BD=Bipolar Disorder) 
 Excluding siblings 
 Relatives of BD Relatives of Controls t P value 
AOO SUD, yrs (SD) 15.33 (2.05) 16.07 (1.88) 1.082 0.290 
AOO NU, yrs (SD) 13.90 (1.51) 15.10 (2.15) 0.877 0.447 
